Stahl S M
Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Harlow, Essex, U. K.
J Neural Transm Suppl. 1988;27:123-32. doi: 10.1007/978-3-7091-8954-2_12.
Recent advances in drug delivery technology are creating novel therapeutic approaches to the treatment of Parkinson's disease with levodopa and dopamine agonists. This article reviews those technologies which can be applied to Parkinson's disease, both for targetting the central nervous system with drugs, as well as for matching the appropriate rate controlled delivery with therapeutic needs. In particular, the possibility exists for eliminating erratic highs and lows of drug delivery to the brain, and to substitute rate controlled, constant drug delivery. Clinical investigations now in progress suggest that new technologies which deliver constant dopaminergic stimulation to patients with Parkinson's disease may not only eliminate the unpredictable swings in therapeutic efficacy in Parkinson patients with the "on/off" effect, but may even have a role in the future in preventing such fluctuations from developing in patients chronically treated with dopaminergic therapies.
药物递送技术的最新进展正在为左旋多巴和多巴胺激动剂治疗帕金森病创造新的治疗方法。本文综述了可应用于帕金森病的技术，这些技术既能将药物靶向中枢神经系统，又能使给药速率控制与治疗需求相匹配。特别是，有可能消除药物向大脑递送时出现的不稳定的高峰和低谷，并代之以速率控制的恒速药物递送。目前正在进行的临床研究表明，向帕金森病患者提供持续多巴胺能刺激的新技术，不仅可以消除帕金森病患者出现“开/关”效应时治疗效果不可预测的波动，甚至在未来可能有助于防止长期接受多巴胺能治疗的患者出现此类波动。
